Insmed reported $-80.97M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Cytokinetics USD -160.3M 9.02M Jun/2026
DBV Technologies USD -61.2M 15.3M Sep/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -80.97M 93.7M Sep/2026
Novartis USD 5.36B 45M Sep/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026